NO20023175L - Kamptotecin beta-alaninestere med topoisomerase I inhibering - Google Patents

Kamptotecin beta-alaninestere med topoisomerase I inhibering

Info

Publication number
NO20023175L
NO20023175L NO20023175A NO20023175A NO20023175L NO 20023175 L NO20023175 L NO 20023175L NO 20023175 A NO20023175 A NO 20023175A NO 20023175 A NO20023175 A NO 20023175A NO 20023175 L NO20023175 L NO 20023175L
Authority
NO
Norway
Prior art keywords
topoisomerase
beta
camptotecin
inhibition
alanine esters
Prior art date
Application number
NO20023175A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023175D0 (no
Inventor
Dolatrai Vyas
Neelakantan Balasubramanian
Mansukh C Wani
Monroe E Wall
Govindarajan Manikumar
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20023175D0 publication Critical patent/NO20023175D0/no
Publication of NO20023175L publication Critical patent/NO20023175L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20023175A 1999-12-29 2002-06-28 Kamptotecin beta-alaninestere med topoisomerase I inhibering NO20023175L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/474,099 US6288072B1 (en) 1999-12-29 1999-12-29 Camptothecin β-alanine esters with topoisomerase I inhibition
PCT/US2000/015033 WO2001049691A1 (fr) 1999-12-29 2000-06-14 ESTERS β-ALANINE DE CAMPTOTHECINE AVEC INHIBITION DE LATOPOISOMERASE I

Publications (2)

Publication Number Publication Date
NO20023175D0 NO20023175D0 (no) 2002-06-28
NO20023175L true NO20023175L (no) 2002-08-29

Family

ID=23882177

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023175A NO20023175L (no) 1999-12-29 2002-06-28 Kamptotecin beta-alaninestere med topoisomerase I inhibering

Country Status (11)

Country Link
US (1) US6288072B1 (fr)
EP (1) EP1254141B1 (fr)
JP (1) JP4704648B2 (fr)
KR (1) KR100762556B1 (fr)
AT (1) ATE302204T1 (fr)
AU (1) AU784602B2 (fr)
CA (1) CA2396030C (fr)
DE (1) DE60022095T2 (fr)
ES (1) ES2246864T3 (fr)
NO (1) NO20023175L (fr)
WO (1) WO2001049691A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403604B1 (en) * 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003043584A2 (fr) * 2001-11-20 2003-05-30 University Of Kentucky Research Foundation Particules liposomales modifiees contenant des promedicaments charges dans le noyau et destines a la liberation controlee des camptothecines
US6482830B1 (en) * 2002-02-21 2002-11-19 Supergen, Inc. Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
ITRM20020306A1 (it) 2002-05-31 2003-12-01 Sigma Tau Ind Farmaceuti Esteri in posizione 20 di camptotecine.
US20040204435A1 (en) * 2003-04-09 2004-10-14 Joachim Liehr Alternating treatment with topoisomerase I and topoisomerase II inhibitors
US7071204B2 (en) * 2003-06-30 2006-07-04 Research Triangle Institute Camptothecin analogs having an E-ring ketone
EP2914600A2 (fr) * 2012-10-30 2015-09-09 Nerviano Medical Sciences S.r.l. Dérivés de 9-bromocamptothécine fonctionnalisés
WO2018209293A2 (fr) 2017-05-11 2018-11-15 The Regents Of The University Of California Nano-émulsions multiples et nanoparticules
CN111171041B (zh) * 2018-11-12 2021-07-27 中国海洋大学 20位取代的喜树碱衍生物及其制备方法和应用
CN111484501A (zh) * 2020-04-22 2020-08-04 沈阳药科大学 羟基喜树碱亚油酸酯小分子前药及其自组装纳米粒的构建

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US564619A (en) * 1896-07-28 Apparatus for dyeing
US5053512A (en) 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5106742A (en) 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5227380A (en) 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US4894456A (en) 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5364858A (en) 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5122526A (en) 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US5049668A (en) 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US5122606A (en) 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US5180722A (en) 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US5340817A (en) 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
DE4119981C1 (fr) 1991-06-18 1993-01-21 Fa. Carl Freudenberg, 6940 Weinheim, De
ES2086643T3 (es) * 1991-10-29 1996-07-01 Glaxo Wellcome Inc Derivados de camptotecina solubles en agua.
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
US5646159A (en) 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US5496830A (en) 1994-09-14 1996-03-05 Johns Hopkins University Inhibition of hemoflagellates by camptothecin compounds
US5614529A (en) 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
GB9504065D0 (en) * 1995-03-01 1995-04-19 Pharmacia Spa Poly-pyrrolecarboxamidonaphthalenic acid derivatives
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
JPH08333370A (ja) 1995-06-08 1996-12-17 Kyorin Pharmaceut Co Ltd 水に可溶な新規フルオロエチルカンプトテシン誘導体、及びその製造方法
CZ133898A3 (cs) * 1995-11-02 1998-08-12 Glaxo Wellcome Inc. Způsob výroby derivátů camptothecinu
WO1997019085A1 (fr) 1995-11-22 1997-05-29 Research Triangle Institute Composes de camptothecine a proprietes combinees d'inhibition de la topoisomerase i et d'alkylation de l'adn

Also Published As

Publication number Publication date
EP1254141A1 (fr) 2002-11-06
US6288072B1 (en) 2001-09-11
DE60022095D1 (en) 2005-09-22
AU5453800A (en) 2001-07-16
JP2003519234A (ja) 2003-06-17
EP1254141B1 (fr) 2005-08-17
KR20020081682A (ko) 2002-10-30
AU784602B2 (en) 2006-05-11
CA2396030A1 (fr) 2001-07-12
KR100762556B1 (ko) 2007-10-04
EP1254141A4 (fr) 2003-05-02
NO20023175D0 (no) 2002-06-28
ATE302204T1 (de) 2005-09-15
ES2246864T3 (es) 2006-03-01
WO2001049691A1 (fr) 2001-07-12
DE60022095T2 (de) 2006-06-08
CA2396030C (fr) 2011-03-15
JP4704648B2 (ja) 2011-06-15

Similar Documents

Publication Publication Date Title
HK1049664A1 (en) Quinazoline derivatives as vegf inhibitors
PL350911A1 (en) Inhibitors of impdh enzyme
AU2001228309A1 (en) N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
AU2002331311A1 (en) Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
HUP0101793A3 (en) Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
NO20054715L (no) Fremgangsmater og mellomprodukter for fremstilling av anti-cancer forbindelser
WO2001044247A3 (fr) Agents et methodes de traitement des maladies hyperplasiques
ID20637A (id) Metode untuk menghambat pembentukan sulfida biogenik
HK1046278B (zh) 作為cdk2抑制劑的吡唑並苯並二氮䓬
WO2003101444A8 (fr) Composes et derives de diaryluree utilises comme inhibiteurs de chk-1 dans le traitement du cancer
NO20021541L (no) 5-beta-sapogenin- og pseudosapogeninderivater samt deres anvendelse ved behandling av demens
NO20023175L (no) Kamptotecin beta-alaninestere med topoisomerase I inhibering
DE69814894T2 (de) Isochinolin derivate als urokinase inhibitoren
PT1144425E (pt) Derivados de monossacaridos como inibidores de adesao celular
AU1189201A (en) Therapeutic compositions including protein kinase c inhibitors
DE60038350D1 (de) Angiotensin-Converting-Enzyme-Hemmer
AU7125700A (en) Enzyme inhibitors
GB9924522D0 (en) Enzyme inhibitors
NO20031745L (no) Inhibisjon av vekstfaktoravhengigheten til tumorceller
WO2005009347A3 (fr) Camptothecine 7-substituee et analogues de camptothecine et leurs procedes de preparation
WO2001044235A3 (fr) Agents et methodes de traitement des maladies hyperplasiques
AU7127000A (en) Enzyme inhibitors
AU1070901A (en) Method of treating cells of the prostate prophylactically or therapeutically
AU2003300551A8 (en) Compounds for the inhibition of non-proteolytic enzymes
AU7127100A (en) Enzyme inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application